Hjertemagnyl

Hjertemagnyl is an oral medication that contains the active ingredient acetylsalicylic acid. It is marketed in the European Union and is supplied as a tablet (strength not specified). As a non‑steroidal anti‑inflammatory drug (NSAID) it is classified as an antiplatelet agent used to reduce the risk of cardiovascular events. The product is intended for oral administration. It is available by prescription in most EU countries.

Hjertemagnyl is prescribed primarily to lower the risk of serious cardiovascular events in patients with established disease or high risk. It is used as part of long‑term secondary prevention strategies.

- Prevention of first‑time myocardial infarction in patients with coronary artery disease. - Prevention of ischemic stroke in individuals with a history of cerebrovascular events. - Secondary prevention of recurrent heart attacks after an initial myocardial infarction. - Secondary prevention of recurrent ischemic strokes following a prior stroke. - Reduction of overall cardiovascular mortality in high‑risk patient populations.

Like other aspirin products, Hjertemagnyl may cause a range of adverse reactions, from mild and frequent to rare but serious.

Common: - Upset stomach, dyspepsia, or mild abdominal pain. - Nausea, vomiting, or loss of appetite. - Minor bruising or prolonged bleeding from cuts. - Heartburn or acid reflux symptoms. - Tinnitus or ringing in the ears.

Serious: - Gastrointestinal ulceration or perforation leading to severe bleeding. - Intracranial hemorrhage or other life‑threatening bleeding events. - Severe allergic reactions such as anaphylaxis or angioedema. - Reye’s syndrome, a rare but fatal condition in children and teenagers. - Kidney impairment or acute renal failure. - Severe liver injury or hepatic failure.

Before starting Hjertemagnyl, patients should consider several safety factors to minimize the risk of complications.

- History of gastrointestinal ulcer, bleeding, or gastritis. - Known hypersensitivity to aspirin or other NSAIDs. - Asthma, nasal polyps, or aspirin‑exacerbated respiratory disease. - Concurrent use of anticoagulants, antiplatelet drugs, or thrombolytics. - Pregnancy, especially the third trimester, unless advised by a physician. - Severe renal or hepatic impairment.

Hjertemagnyl can affect the activity of several other medicines; some combinations should be avoided while others require careful monitoring.

Avoid: - Warfarin, direct oral anticoagulants, or other antithrombotic agents. - Other non‑steroidal anti‑inflammatory drugs (e.g., ibuprofen, naproxen). - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs).

Use with caution: - Corticosteroids, which increase gastrointestinal bleeding risk. - Antihypertensive drugs, as aspirin may reduce their effectiveness. - Lithium, methotrexate, or other drugs with narrow therapeutic windows.